As per the latest data released by Transforming Access to Student Outcomes in Higher Education (TASO) and the Policy Institute at King's College London, the number of UK students reporting mental health difficulties tripled. The estimate reveals that around 300,000 students could now be experiencing mental health struggles. Of the total, 18% of students reported some kind of mental health issue in 2024.

As per the reports, this estimate is triple what was reported in 2017, where it was at 6%. Experts also say that Covid-19 pandemic is "often considered to have contributed to this, it does not explain the ongoing rise in mental health difficulties." Another reason could also be the "changing definition and increasing openness about mental health" which has led to a rise in numbers. The report notes, "This trend pre-dates the Covid-19 pandemic and the cost-of-living crisis. Although these factors play a part in students' deteriorating mental health, they cannot therefore be the only explanation."

How Did The Report Conclude?

The report drew data collected over the latest Student Academic Experience Survey of 93,212 students. From the survey, it was found that there exist significant disparities between demographic groups, with women being twice as likely to report mental health difficulties, about 22% as compared to men, at 11%.

What Did The Results Reveal?

The results revealed that students who identified as LGBTQ experienced the highest rates of mental health challenges. This has actually lessened the hope that conditions for LGBTQ students are improving, which may not have been a positive case.

Of them, 42% are bisexual and lesbian students, whereas last year it was 35% and 32% respectively. The report also noted that mental health difficulties among lesbian women and gay men rose three times the rate of straight people, and among bisexual and asexual people, it was twice as high. For trans students, the number jumped from 25% in 2023 to 40% in 2024.

Is The LGBTQ+ Prone To Mental Health Crisis?

As per the Child Mind Institute, being LGBTQ+ does not cause mental health problems, but because these kids often face factors like rejection, discrimination and violence, they are at a higher risk of challenges including depression, anxiety, and even attempting suicide.

A UTAH Health study quotes Anna Docherty, PhD, LP, assistant professor of psychiatry at Huntsman Mental Health Institute that, "likely with any identity, feeling different - or worse, unaccepted as you are is a significant risk factor of mental health struggle." The data reveals that LGBTQ+ teens are six times more likely to experience symptoms of depression than non-LGBTQ+ identifying teens. They are also more than twice as likely to feel suicidal and more than four times as likely to attempt suicide. In the US alone, 48% of transgender adults report that they have considered suicide in the last year, compared to 4% of the overall population.

What Do These Findings Mean?

TASO's academic lead and professor of public policy at King's College London, Michael Sanders said, "LGBTQ students and women bear the brunt of the rise in declining mental health and urgent action is needed to understand and address these trends."

An indigenous low-cost point-of-care (PoC) testing approach has shown promise in making screening for Human Papillomavirus (HPV) more affordable and accessible, potentially improving the early detection of cervical cancer, according to a joint study led by researchers from AIIMS, ICMR, and the WHO's International Agency for Research on Cancer (IARC).

The study, published in the International Journal of Cancer, found that PoC tests have the potential to become scalable, low-cost screening tools in India and other low- and middle-income countries (LMICs).

The objective of the study was to evaluate indigenous HPV DNA testing platforms for use in primary cervical cancer screening.

Four Indigenous Tests Evaluated

While several Indian HPV tests have been developed, many had not yet been validated against the international standards laid down by the WHO.

The study evaluated four point-of-care tests developed by 3 Indian companies:

• Genes2Me – HPV-Q
• Mylabs India – PathoDetect HPV-7 and PathoDetect HPV-14
• Molbio Diagnostics – Truenat HR-HPV-Plus

Each test was developed by repurposing existing COVID-19 RT-PCR platforms. HPV-Q and PathoDetect HPV-14 can detect all 14 high-risk HPV types, while PathoDetect HPV-7 detects seven high-risk types: 16, 18, 31, 33, 45, 52, and 58.

How the Tests Performed

Also read: PM Modi Launches Nationwide Free HPV Vaccination Drive; A Landmark Step, Says WHO

To assess performance, researchers analyzed 1,159 cervical samples collected from studies conducted in Argentina and Costa Rica.

The results showed:

• Truenat HR-HPV-Plus: Sensitivity 80.4%, specificity 91.5% — met IARC validation criteria.
• PathoDetect HPV-7: Sensitivity 68.1%, specificity 89.0% — lower sensitivity.
• HPV-Q and PathoDetect HPV-14: Did not meet validation criteria.

Indigenous Platforms Can Be Game-Changers

"This study demonstrates that indigenous platforms can achieve clinical validation, quality standards, and accuracy comparable to global gold-standard tests. It will be a game-changer for cervical cancer prevention and early detection in India," said lead author Dr Neerja Bhatla, Professor Emeritus, NCI and former Head of the Department of Obstetrics & Gynecology at AIIMS New Delhi.

Dr Shalini Singh, Director of ICMR-NICPR, added that HPV DNA testing at age 35 and again at age 45 is central to WHO's cervical cancer elimination strategy, but high costs remain a major barrier in LMICs.

"Affordable indigenous solutions are essential to expand screening coverage and reduce disease burden," she said.

High Burden Of Cervical Cancer: Why HPV Testing Matters

Read More: HPV Vaccine Can Help Curb Rising Head And Neck Cancers, Says Top US Doctor

Cervical cancer continues to be a major public health challenge in India, with around 127,000 new cases and 80,000 deaths reported annually.

Globally, cervical cancer is the fourth most common cancer in women. According to WHO data for 2022, there were approximately 662,000 new cases and 348,000 deaths worldwide.

Regular screening of women over 30 years of age every 3-5 years can help detect precancerous and cancerous lesions early. However, screening coverage in India has remained low despite the inclusion of visual inspection with acetic acid (VIA) in the national screening program for breast, oral, and cervical cancers.

Persistent infection with carcinogenic HPV types is the necessary cause of cervical cancer. WHO recommends a transition to HPV testing as the preferred strategy for cervical cancer elimination.

Using validated HPV tests, only two rounds of screening — at ages 35 and 45 — may be sufficient to help achieve elimination targets. However, most existing HPV tests are expensive, require sophisticated laboratory infrastructure, and are not easily available at last-mile health facilities.

The researchers said that the point-of-care HPV testing approach, thus, could be a major breakthrough, enabling affordable diagnostics and even same-day treatment for women who test positive.

Potential for Nationwide Rollout

The researchers noted that while the recently introduced national HPV vaccination campaign will benefit younger generations, there remains an urgent need to expand HPV testing for women over 30 who are currently at risk of cervical cancer.

Dr Showket Hussain of the ICMR-National Institute of Cancer Prevention and Research (NICPR), Noida, said the validated platform has strong potential for integration into national screening programs because district-level healthcare personnel are already familiar with similar testing systems.

"Future advancements such as self-sampling and high-throughput adaptations could further enhance accessibility," he said.

The findings are expected to support India's cervical cancer elimination goals while offering a scalable model for other low-resource settings globally.

Cancer patients in India, already affected by shortages of critical chemotherapy drugs, are now set to face higher costs after the government approved a price hike.

Facing significant shortages are Cisplatin and Carboplatin — the two platinum-based drugs that form the backbone of treatment for common cancers such as oral cancer, breast cancer, ovarian cancer, cervical cancer, esophageal cancer, and testicular cancer.

Shortages Disrupt Cancer Treatment

The shortage of these essential chemotherapy medicines is disrupting care across hospitals and cancer centers, with several doctors pointing out that a substantial proportion of chemotherapy protocols for solid tumors rely on one of these platinum-based agents.

The drugs have been facing shortages as companies find it difficult to sustain production amid rising manufacturing costs linked to the ongoing conflict in the Middle East.

The two drugs, often prescribed in combination and with no alternatives, are derived from platinum, a precious metal whose cost has surged due to the Middle East conflict and the closure of the Strait of Hormuz.

Rising Production Costs Hit Manufacturers

Also read: India Revises Folic Acid Measurement Unit to Prevent Dosage Errors

"The production cost has increased because the API, or active pharmaceutical ingredient, which is imported from abroad, has become more expensive. As a result, manufacturing costs have gone up, but the MRP has not increased," Dr Shyam Agarwal, Senior Consultant, Medical Oncology at Sir Ganga Ram Hospital, told HealthandMe.

As companies have struggled to sustain production amid rising manufacturing costs, they approached the government seeking a revision of the price cap.

Drugmakers reportedly sought price revisions for 82 medicines, citing substantial increases in production costs due to the US-Iran conflict linked to the Hormuz crisis and other factors.

Government Approves Higher Prices

In response, the National Pharmaceutical Pricing Authority (NPPA), following permission from the Union government's Department of Pharmaceuticals (DoP), has increased maximum retail prices for four drugs, including the life-saving cancer medicines Cisplatin and Carboplatin, and two anti-tetanus injections.

While the move is aimed at restoring supplies, it has also raised concerns about affordability for patients already battling a costly disease.

The NPPA is the country's drug price regulator and functions under the DoP, Ministry of Chemicals and Fertilizers.

NPPA Asked to Review Cost Increases

Read More: India's Maternal Mortality Ratio Drops From 130 To 87 In Last 10 Years: Govt

The ministry directed the pricing authority to determine how much prices could be increased.

The formula suggested: "The Standing Committee recommended a 10 per cent increase per year from the last fixation with a ceiling of 50 per cent, which could also be a guide, but the primary principle should be cost increase," News18 reported.

The DoP has further advised the NPPA to examine increases in raw material costs for these drugs while determining any price revisions. It has also asked the regulator to assess similar requests from the pharmaceutical industry, where price hikes have been sought due to higher raw material costs.

India's Ministry of Health has notified an amendment to the Drugs Rules, 1945, replacing the unit of measurement for folic acid under Schedule V from "mg" (milligrams) to "mcg" (micrograms).

The amendment has been brought into effect through the Drugs (Fourth Amendment) Rules, 2026, notified vide Gazette Notification G.S.R. 444(E) dated June 1, 2026. The notification will come into force after six months, according to the Ministry.

The move aims to avoid unnecessary confusion, reduce the chances of misinterpretation, and prevent incorrect administration of dosages of vitamin B9 — essential for the production of healthy red blood cells, especially during pregnancy.

The change follows the publication of draft rules in January 2026 and consideration of objections and suggestions received from stakeholders.

What Does The New Notification Say?

Also read: India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

As per the notification, in Schedule V of the Drugs Rules, 1945, under paragraph 2 relating to standards for patent or proprietary medicines, the entry against "Folic acid" in the unit column has been amended. The earlier unit "mg" has now been substituted with "mcg".

The amendment will correct the unit of measurement, bringing it in line with internationally accepted dosing standards for folic acid, which is routinely prescribed and labelled in micrograms. This correction is also important because lower doses of folic acid are used prophylactically in situations such as pregnancy to prevent infant malformations. Higher doses, however, may be used to address specific conditions such as neural tube defects, Medical Dialogues reported.

The Ministry stated that the amendment has been made after consultation with the Drugs Technical Advisory Board (DTAB) and in exercise of the powers conferred under Sections 12 and 33 of the Drugs and Cosmetics Act, 1940.

According to the notification, the Drugs (Fourth Amendment) Rules, 2026, will come into force six months from the date of publication in the Official Gazette, giving manufacturers and other stakeholders sufficient time to make necessary compliance-related changes in product documentation, labelling, and regulatory records.

Why Is Folic Acid Important?

Read More: Introducing Eggs Before Age One May Lower Allergy Risk by 17%: Study

According to the American College of Obstetricians and Gynecologists (ACOG), folic acid is one of the most important nutrients in prenatal vitamins. This B vitamin helps create the baby's neural tube — the structure that eventually forms the brain and spinal cord.

Beyond pregnancy, people who do not consume enough folate- or folic acid-rich foods may develop folate deficiency. People with celiac disease and inflammatory bowel disease, which prevent the small intestine from absorbing nutrients properly, may also have low folate levels, as per the Mayo Clinic.

Folate is found mainly in

• dark green leafy vegetables,
• beans,
• peas,
• nuts.

Fruits rich in folate include

• oranges,
• bananas,
• melons,
• papayas.

The recommended daily amount of folate for adults is 400 micrograms (mcg). People who are planning a pregnancy or could become pregnant should get 400 to 800 mcg of folic acid daily.

Importantly, taking too much folic acid, especially over 1,000 mcg daily without a doctor's advice, can mask a vitamin B12 deficiency, potentially causing irreversible nerve damage and may lead to side effects such as bitter taste, nausea or sleep problems, with potential links to increased risks in pregnancy like autism or insulin resistance.